Novavax, Inc. (NASDAQ: NVAX) declared approbatory results from the ordinal initiate of the Phase I/IIa manlike clinical effort of its pandemic contagion virus-like particle (VLP) immunogen candidate. The vaccine, which does not include an adjuvant, evoked burly neutralizing antibody responses. Novavax’s VLP politician is directed against the H5N1 A/Indonesia/05/2005 avian contagion strain.